- Home
- EDRY vs XLO Comparison
EDRY vs XLO Comparison
Compare EDRY & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDRY | XLO |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7M | 41.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EDRY | XLO |
|---|---|---|
| Price | $16.25 | $0.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 4.0K | ★ 581.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $626.78 |
| Revenue Next Year | $19.70 | $79.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.60 | $0.50 |
| 52 Week High | $16.14 | $1.22 |
Technical Indicators
Market Signals| Indicator | EDRY | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 68.71 | 44.48 |
| Support Level | $13.64 | $0.52 |
| Resistance Level | $14.85 | $0.61 |
| Average True Range (ATR) | 0.68 | 0.04 |
| MACD | 0.16 | 0.00 |
| Stochastic Oscillator | 83.26 | 53.17 |
Price Performance
Historical ComparisonAbout EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.